News Bausch + Lomb Corporation Toronto S.E.

Equities

BLCO

CA0717051076

Market Closed - Toronto S.E. Other stock markets 04:10:00 2024-05-03 pm EDT			5-day change	1st Jan Change
18.25 ^CAD	-3.69%		-9.47%	-19.50%

May. 02	RBC Capital Reviews Bausch + Lomb's Q1 Results	MT
May. 02	Deutsche Bank Adjusts Bausch + Lomb Price Target to $14 From $18, Maintains Hold Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bausch Health Announces First Quarter 2024 Results	May. 03	AQ
RBC Capital Reviews Bausch + Lomb's Q1 Results	May. 02	MT
Deutsche Bank Adjusts Bausch + Lomb Price Target to $14 From $18, Maintains Hold Rating	May. 02	MT
Needham Says Bausch + Lomb's Q1 Showed a "Strong Start" to The Year	May. 01	MT
Bausch + Lomb Q1 Loss Widens, Revenue Increases	May. 01	MT
Transcript : Bausch + Lomb Corporation, Q1 2024 Earnings Call, May 01, 2024	May. 01
Bausch + Lomb Q1 Net Loss Widens, But Revenue Higher; Raises 2024 Revenue Growth Guidance	May. 01	MT
Bausch + Lomb: Q1 Earnings Snapshot	May. 01	AQ
Bausch + Lomb Brief: Raising Full-Year 2024 Constant Currency Revenue Growth Guidance	May. 01	MT
Bausch + Lomb Brief: Q1 Adjusted EBITDA (non-GAAP) of US$180 Million	May. 01	MT
Bausch + Lomb Brief: Q1 Revenue of US$1.099 Billion; GAAP Net Loss Attributable of $167 Million	May. 01	MT
Bausch + Lomb Announces First-Quarter 2024 Results	May. 01	BU
Bausch + Lomb Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 01	CI
Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting	Apr. 29	BU
Bausch + Lomb Says Study Shows Improvements in Dry Eyes With Nutritional Supplement	Apr. 25	MT
Bausch + Lomb Reports "Statistically Significant" Results From Study of Nutritional Supplement for Dry Eyes	Apr. 25	MT
Bausch + Lomb Brief: Announcing "Statistically Significant" Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes	Apr. 25	MT
Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes	Apr. 25	BU
Bausch + Lomb Corporation Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes	Apr. 25	CI
RBC Previews Bausch Health's Q1, Trims Target to US$11	Apr. 23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Bausch + Lomb Corporation Toronto S.E.

Equities

BLCO

CA0717051076

Summary

Filters